OR WAIT null SECS
The evolution of therapeutic modalities drives the adoption of single-use technologies.
Despite a growing number of biosimilar approvals, market uptake remains a challenge.
Given the criticality of fill/finish processes, it is clear that automation is the next technological step.
October 18, 2024
Cell and gene therapy experts Fabian Gerlinghaus, Dr. Claudia Zylberberg, and Benjamin McLeod weigh in on hot topics in CGT.
October 17, 2024
The establishment of this new center aims to expedite R&D processes, reduce costs, and potentially lead to accelerated discovery of new candidate therapies.
The new center's design will prioritize integration of the entire supply chain, with the aim of accelerating product development and autonomous production capacity in alignment with EU priorities.
October 12, 2024
SK pharmteco will be the preferred manufacturing partner for AVG-101, AaviGen’s lead gene therapy product.
Evonik's plant-based squalene, PhytoSquene, used in parenteral drug delivery applications, won the CPHI Excellence in Pharma Award in the “Sustainability” category.
October 11, 2024
Aseptic fill/finish of biopharmaceuticals requires an understanding of the structure and limitations of each molecule.
In this article, the authors explored the elimination of a water rinse and blow down following the caustic wash step, examining potential safety considerations, the effect on the quality of the cleaning process, and the potential benefit of implementing this change.
At CPHI Milan, Nicolas Camper, senior director—Bioconjugation Chemistry, Abzena, spoke about new developments in ADC technologies, including the role of complex chemistries.
October 10, 2024
Solving the challenge of better-stabilized temperature-sensitive biomolecules hinges on innovative formulation strategies.